FeynMed Solutions
FeynMed Solutions develops nanocrystalline silver wound dressings, including the Trivera™ product, designed to treat burns, surgical wounds, diabetic foot ulcers, and pressure ulcers. The dressings deliver sustained antimicrobial activity that combats infection-causing microbes, reduces inflammation, and preserves healthy tissue without promoting antimicrobial resistance. The technology is manufactured with atomic-scale control and is being developed for the FDA's 510(k) regulatory pathway as a Class II medical device.
- Medical Devices
- Healthcare Technology
- New Materials
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Chronic and acute wounds such as diabetic foot ulcers, pressure ulcers, surgical sites, and burns are highly susceptible to persistent infections that standard antibiotics and legacy silver treatments often fail to control. These infections drive non-healing, frequently leading to amputation, with five-year mortality exceeding 70 percent after amputation for diabetic foot ulcers, and septicemia reported in roughly 40 percent of pressure-ulcer-associated deaths.
Solution
FeynMed Solutions provides nanocrystalline silver wound dressings, including the Trivera™ product, engineered at the nanometre scale with a patented manufacturing process that ensures consistent, sustained release of antimicrobial silver species. The dressing addresses three simultaneous wound problems—infection, inflammation, and tissue damage—through a single mechanism, offering broad-spectrum antimicrobial activity including against drug-resistant strains, anti-inflammatory effects, and tissue compatibility. Published testing shows log10 reductions exceeding 6 against S. aureus and 7 against P. aeruginosa, well past the 99.99% kill threshold. The technology is being developed for the FDA's 510(k) regulatory pathway as a Class II medical device, with parallel licensing under Health Canada's Medical Devices Regulations.
Target Audience
Primary customers are healthcare teams and clinicians treating patients with diabetic foot ulcers, pressure ulcers, surgical site infections, and burns, particularly where standard treatments have failed or where antimicrobial resistance is a concern.
Features
- Nanocrystalline silver structured at the nanometre scale with physical and chemical properties controlled by a patented manufacturing process (US patent 12,472,102)
- Sustained, consistent availability of antimicrobial silver species, replicable batch after batch, avoiding bolus release and interactions with bodily fluids
- Multi-mechanism antimicrobial action that kills through several pathways simultaneously, reducing the risk of bacteria developing resistance
- Anti-inflammatory activity documented in published preclinical studies, addressing inflammation alongside infection
- Tissue-compatible design that acts on pathogens while limiting impact on surrounding healthy tissue
- Manufacturing operations being validated to ISO and cGMP standards for clinical-grade output